Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice

• المؤلفون الرئيسيون: Xiaotong Song (مؤلف), Luchang Cao (مؤلف), Baoyi Ni (مؤلف), Jia Wang (مؤلف), Xiaoyan Qin (مؤلف), Xiaoyue Sun (مؤلف), Bowen Xu (مؤلف), Xinmiao Wang (مؤلف), Jie Li (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of lung cancer, especially in the first-line treatment of advanced NS...